Ardelyx (NASDAQ:ARDX) Given Outperform Rating at Wedbush : v

Wedbush reissued their outperform rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a research note released on Friday, Benzinga reports. They currently have a $13.00 target price on the biopharmaceutical company’s stock. Wedbush also issued estimates for Ardelyx’s Q4 2025 earnings at $0.14 EPS and FY2028 earnings at $1.69 EPS. A number of […]

Related Keywords

United States , Davidp Rosenbaum , Raymond James , Justina Renz , Blackrock Inc , Nasdaq , Citigroup , Securities Exchange Commission , Renaissance Technologies , Ardelyx Inc , Eventide Asset Management , Cantor Fitzgerald , Free Report , Moderate Buy , Get Free Report , Exchange Commission , Street Corp , Asset Management , Ardelyx Daily , Ardelyx , Nasdaq Ardx , Cardx , Medical , Reiterated Rating , Wedbush ,